Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Bioxodes
Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens
November 14, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
October 07, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
September 11, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
April 24, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
March 05, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
February 12, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
December 19, 2024
From
Bioxodes
Via
GlobeNewswire
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
August 21, 2024
From
Bioxodes
Via
GlobeNewswire
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
June 27, 2024
From
Bioxodes
Via
GlobeNewswire
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
May 16, 2024
From
Bioxodes
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.